Hayden E. Klein

It’s important for clinicians to listen to patients and know how heart disease may affect women differently than men, said Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.

Adults aged 70 and older were significantly more likely to develop congestive heart failure if they also experienced olfactory impairment.

John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).

Children aged 10 years and older with type 2 diabetes can now improve their glycemic control with a drug previously only approved for adults.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed challenges in Duchenne muscular dystrophy (DMD) treatment access and how policy changes may support patients with DMD.

The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.

Jeff Levin-Scherz, MD, MBA, population health leader at WTW, explains that obesity care in the US is inconsistent and costly, with significant gaps across Medicare, Medicaid, and employer-based insurance.

Ronesh Sinha, MD, attributes the rising rates of heart disease to sedentary lifestyles, stress, and health inequities, while advocating for digital health solutions to improve preventive care.

According to new research from Jordan, patients with both heart failure (HF) and diabetes had a higher prevalence of HF with preserved ejection fraction (HFpEF), elevated cholesterol, low-density lipoprotein, and impaired kidney function.

Cardiovascular disease (CVD) risk was reduced by 1.2% in the intention-to-treat analysis and 5% in the per protocol analysis for adults aged 75 and older.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed the most promising areas of research in Duchenne muscular dystrophy (DMD), as well as the mechanisms of gene therapies for DMD.

Patients who took the weekly glucagon-like peptide 1 (GLP-1) receptor agonist were 21% less likely to experience major kidney disease events and 29% less likely to die due to cardiovascular causes.

From 2015 to 2020, the number of patients opting for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) over redo surgical aortic valve replacement (SAVR) rose significantly, from 35.3% to 62.5%.

Vamorolone (Agamree) is a first-in-class corticosteroid to treat Duchenne muscular dystrophy (DMD) in patients 2 years and older.

Patients taking semaglutide for a year saw significant improvements in exercise capacity and lost 2.9% more body weight compared with patients taking placebo.

New research has shown a link between children’s consumption of ultraprocessed foods and their risk of obesity and other cardiometabolic problems.

Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and opinions on Medicare coverage of glucagon-like peptide-1 (GLP-1) drugs.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.

Mila Felder, MD, FACEP, emergency physician and vice president, Wellbeing for All Teammates, Advocate Health, discusses how to implement well-being into peer support within oncology care.

While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.

Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.

During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.

Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.

Survey results from more than 1500 patients with diabetes revealed that 57% believed glucagon-like peptide-1 (GLP-1) weight loss drugs alone could be a "silver bullet" for managing their health goals.

The novel intravesical drug delivery system releases erdafitinib locally within the bladder while limiting systemic toxicities.

Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.

Updated findings from SunRISe-1 also showed that all but 1 responder achieved complete response within 12 weeks of treatment with the targeted gemcitabine delivery system.

Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future prostate cancer risk.

The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.

Researchers also estimated that more than 700,000 Americans with diabetes could lose insurance coverage if these proposed retractions are put into place, with some new policies already in effect.